Physician profile
Prashant Krishnan
NPI 1689883993
$3,740.61
in general payments reported to CMS, 2019-2025
27 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2021: $342 · 2022: $463 · 2023: $850 · 2024: $936 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $45.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.42 |
| Education | $45.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $619.58 | 2019-2025 | General - Biliary Devices, Axios |
| Abbvie INC. | $611.60 | 2019-2025 | |
| Medtronic, INC. | $297.42 | 2022-2024 | Gi Genius |
| Takeda Pharmaceuticals U.S.A., INC. | $267.40 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $244.43 | 2022-2024 | |
| Celgene Corporation | $226.61 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $216.86 | 2021-2025 | Tremfya, Stelara, Simponi |
| Celltrion USA INC. | $167.43 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.01 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $115.32 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $114.61 | 2022-2025 | Rebyota |
| Braintree Laboratories, INC. | $84.29 | 2021-2022 | |
| Lilly USA, LLC | $81.32 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $75.11 | 2025 | Iqirvo |
| Genentech, INC. | $68.87 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $56.80 | 2024 | |
| Qol Medical, LLC | $56.09 | 2021-2025 | Sucraid |
| Pfizer INC. | $49.41 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $46.10 | 2024 | Dupixent |
| Redhill Biopharma INC. | $44.85 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Alexion Pharmaceuticals, INC. | $24.88 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $23.24 | 2024 | Dificid |
| Genzyme Corporation | $21.58 | 2024 | |
| Laborie Medical Technologies Corp. | $19.94 | 2023 | |
| Ardelyx, INC. | $19.11 | 2022 | |
| Novo Nordisk INC | $18.18 | 2025 | Wegovy |
| Baxter Healthcare | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.